All Clinical Trials
Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.
322 trials found
Drug |
NCT# |
||
|---|---|---|---|
| Imatinib | A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors | 2 |
|
| None | Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial | ||
| Avapritinib (CS3007) | A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor | 1/2 |
|
| Imatinib + BGJ398 | BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | 1/2 |
|
| Imatinib + MEK162 | MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | 1b/2 |
|
| Imatinib + PDR001 | PDR001 Plus Imatinib for Metastatic or Unresectable GIST | 1/2 |
|
| Imatinib + Selinexor | Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (SeliGIST) | 1/2 |
|
| THE-630 | A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | 1/2 |
|
| Imatinib | Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) (Japan CSTI571BJP07) | 4 |
|
| Imatinib + Sunitinib + Regorafenib | Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients | 4 |
|
| Sunitinib | Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor (GIST) | 4 |
|
| Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) | 3 |
||
| Avapritinib or Regorafenib | (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | 3 |
|
| Bezuclastinib plus Sunitinib | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | 3 |
|
| Crenolanib (CP-868,596) | Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST | 3 |
|
| Famitinib | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib | 3 |
|
| Imatinib | Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (S0033) | 3 |
|
| Imatinib | Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery (ACOSOG-Z9001) | 3 |
|
| Imatinib | Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor (EORTC-62024) | 3 |
|
| Imatinib | Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) (SSGXVIII/AIO) | 3 |
|
| Imatinib | Open-Label Trial of Glivec With Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors | 3 |
|
| Imatinib | Prospective Multicentric Randomized Study of Glivec® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance | 3 |
|
| Imatinib | Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor (EORTC-62005) | 3 |
|
| Imatinib | Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate | 3 |
|
| Imatinib | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | 3 |
|
| Imatinib | Rechallenge of Imatinib in GIST Having no Effective Treatment (RIGHT) | 3 |
|
| Imatinib | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist) | 3 |
|
| Imatinib | Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST | 3 |
|
| Imatinib + Bevacizumab | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | 3 |
|
| IPI-504 | Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib | 3 |
|
| L-carnitine | L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors | 3 |
|
| Masitinib or Sunitinib | Masitinib 2nd Line versus Sunitinib in Advanced GIST | 3 |
|
| Masitinib, (AB1010) | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment | 3 |
|
| Nilotinib | Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST) | 3 |
|
| Nilotinib | Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension | 3 |
|
| Nilotinib | Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib | 3 |
|
| Nilotinib or Imatinib | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST) | 3 |
|
| Nilotinib or Imatinib | Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1) | 3 |
|
| QINLOCK Ripretinib DCC-2618 | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus) | 3 |